Innovative Cannabis Product C3 International has developed Idrasil™, a standardized 25mg all-natural medical cannabis pill that is reimbursable by insurance providers in California, representing a unique position in the cannabinoid therapeutics market with high potential for expansion into other regions or healthcare sectors.

Growing Industry Presence With recent product launches and strategic hires of prominent advisors like Ken Shamrock and Gary Hall Jr., C3 International is strengthening its market credibility and visibility, which creates opportunities to introduce their healthcare solutions to a broader network of medical institutions and healthcare providers.

Targeted Market Focus Operating primarily within California's medical and hospital communities, C3 offers opportunities to partner with healthcare organizations, insurance companies, and pharmaceutical distributors focused on innovative, natural, and reimbursable therapeutics.

Tech-Driven Growth Utilizing an advanced tech stack including WordPress, MySQL, and SEO tools, C3 is positioned to effectively promote its products online and scale digital marketing efforts, opening doors for digital partnerships and online sales strategies.

Financial Potential With revenues estimated between 1 and 10 million dollars, C3 has demonstrated market traction and can benefit from targeted sales outreach to healthcare providers, pharmacies, and insurance partners looking to expand their portfolio with approved, natural cannabinoid therapeutics.